DiabetesSeriesLive

CME Presentations

Evolution of Insulin Replacement Therapy


Presentations


Speakers


CME Information

The Evolution of Insulin Replacement Therapy: New Perspectives and Clinical Applications

Presented by Joslin Diabetes Center in Joint Providership with PlatformQ Health Education, LLC

ACKNOWLEDGEMENT These activities are supported by educational grants from Novo Nordisk Inc. and Medtronic, Inc.

TUITION Complimentary

ACCREDITATION STATEMENT The activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Internet Activities Joslin Diabetes Center designates these live activities for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

Enduring Material Joslin Diabetes Center designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION Live Internet Activities Thursday, September 14, 2017 from 3:00 PM EST – 4:00PM EST. •Insulin Options for Diabetes: Update on their Evolution Thursday, October 19, 2017, from 1:00 PM EST – 2:00 PM EST •Advancing to Insulin Therapy for Type 2 Diabetes: The Impact of the New Insulin Options Thursday, November 30, 2017, from 12:00 PM EST – 2:00 PM EST •12:00 PM – 1:00 PM EST: Physiologic Insulin Replacement: Practical Approaches for the Primary Care Provider •1:00 PM – 2:00 PM EST: The Evolution of Glycemic Monitoring and Insulin Delivery Devices: Why the Primary Care Provider Should Understand the Options

Enduring Material The enduring material will be available from September 14, 2017 – May 30, 2018.

LEARNING OBJECTIVES At the conclusion of these activities, participants will be able to:

Insulin Options for Diabetes: Update on their Evolution
Identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations
Discuss the clinical importance of similarities and differences between a biosimilar insulin and a reference insulin
Describe key, clinically relevant data derived from pivotal trials of new and emerging insulin products
Advancing to Insulin Therapy for Type 2 Diabetes: The Impact of the New Insulin Options
Recognize the indications for advancement to insulin replacement therapy for people with T2DM
Identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations
Describe initiation and titration methods for new insulin-based therapies to optimize achievement of glycemic goals while minimizing adverse effects
Physiologic Insulin Replacement: Practical Approaches for the Primary Care Provider
Recognize the indications for advancement to insulin replacement therapy for people with T2DM
Describe initiation and titration methods for new insulin-based therapies to optimize achievement of glycemic goals while minimizing adverse effects
Discuss strategies to overcome patient and clinician barriers to the successful initiation and utilization of insulin therapy in the context of the new insulin-based therapies, and monitoring and delivery devices
The Evolution of Glycemic Monitoring and Insulin Delivery Devices: Why the Primary Care Provider Should Understand the Options
Recognize the indications for advancement to insulin replacement therapy for people with T2DM
Describe initiation and titration methods for new insulin-based therapies to optimize achievement of glycemic goals while minimizing adverse effects
Discuss strategies to overcome patient and clinician barriers to the successful initiation and utilization of insulin therapy in the context of the new insulin-based therapies, and monitoring and delivery devices
 

INTENDED AUDIENCE Primary Audience: US–based primary care providers, clinical endocrinologists/diabetologists, nephrologists, cardiologists, emergency department specialists, pharmacists, and other clinicians caring for patients with type 2 diabetes mellitus (T2DM).

METHOD OF PARTICIPATION There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 4 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURES As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non–healthcare–related companies, which are exempt. Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected. If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center. The faculty and planning committee members for this program have disclosed the following:

Faculty

  • Dr. Richard S. Beaser*†, Senior Staff Physician and Medical Director of CME, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
  • Anne L. Peters, MD, Director, Clinical Diabetes Program and Professor, Keck School of Medicine, University of Southern California, is a consultant for and participates as a speaker for promotional activities for Abbott Diabetes Care, Becton Dickinson, Bigfoot, Boehringer Ingelheim, Dexcom, Eli Lilly and Co, Inc., Janssen, Lexicon, Livongo, Medscape, Merck, Novo Nordisk, Omada Health, Sanofi, and Science 37. She receives grant/research support from Dexcom, and participates as a speaker for promotional activities for Johnson & Johnson Diabetes Institute.
  • Jeremy H. Pettus, MD, Assistant Professor of Medicine, Division of Endocrinology, University of California, San Diego, is a consultant for and participates as a speaker for promotional activities for Sanofi, Novo Nordisk, and Insulet Corporation.
  • Richard E. Pratley, MD, Samuel E. Crockett Chair in Diabetes Research and Director, Florida Hospital Diabetes Institute, and Adjunct Professor, Sanford Burnham Prebys Medical Discovery Institute, receives grant/research support from Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Inc., Lilly, Merck, Novo Nordisk, Sanofi-Aventis US, LLC, and Takeda. He is a consultant for AstraZeneca, Boehringer-Ingelheim, Eisai, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Lilly, Merck, Novo Nordisk, Pfizer, and Takeda. He participates as a speaker for promotional activities for Novo Nordisk and Takeda.
  • Alissa Segal, PharmD, CDE†, Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences University, and Clinical Pharmacist and Diabetes Educator, Joslin Diabetes Center, is a consultant for Eli Lilly and Co., Inc. and Boehringer Ingelheim Pharmaceuticals, Inc.

Planning Committee

  • Agnes Yang, MD, Medical Director, PlatformQ Health Education, has no relevant financial relationships
  • Karen Greb-Murphy, Senior Program Manager, PlatformQ Health Education, has no relevant financial relationships

Joslin CME Advisory Committee

  • Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
  • Erin Kelly, CDE, Adult Diabetes Educator, Joslin Diabetes Center, is a contract pump trainer for Medtronic, Tandem, Omnipod and Animas.
  • Melinda Maryniuk, CDE, Director, Clinical Programs, Joslin Diabetes Center, has no relevant financial relationships.
  • Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health
  • Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, is a consultant for and receives grant / research funding from Boehringer Ingelheim Pharmaceuticals, Inc.
  • Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.

* also on the Planning committee † also on the CME Advisory Committee

CONTACT INFORMATION Please send content inquiries to: cme@joslin.harvard.edu. For technical problems with the site or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.

DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material. The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.